HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Summary

This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini. This protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in Eswatini. The secondary objectives include examining the safety profiles of the two-dose 9vHPV regimen in those living with HIV and the three-dose 9vHPV regimen in HIV-uninfected young women, as well as measuring the completion of the vaccination series among those living with HIV and those who are not infected with HIV.

Timeline

Start

2022-04-01

Primary completion

2024-12-09

Completion

2024-12-09

Publications

• Nuwagaba-Biribonwoha H, Lamb MR, Dlamini X, Zerbe A, Anabwani-Richter FA, Zech JM, Hsu A, Mabuza N, Lukhele NM, Fayorsey R, Sahabo R, Nkambule R, El-Sadr WM, Abrams EJ. Immunogenicity of 2 versus 3 dose HPV vaccination by HIV infection status in Eswatini. Vaccine. 2026 Jul 11;85:128692. doi: 10.1016/j.vaccine.2026.128692. Epub 2026 May 16.

Drugs

Indications